The company’s main platform is called Immunopulse. Immunopulse helps to deliver specific therapies into tumors. Using this platform, they can combine therapies together in order to better treat patients
Oncosec is partnered with pharma-giant Merck ( MRK ) with it’s anti-PD-1 therapy called KEYTRUDA.
Another exciting point is that Point 72 Asset Management just recently added shares. That fund is ran by legendary investor Steve Cohen. He owns over 2M shares and is the top shareholder of Oncosec stock.
He has a strong track record of picking some of these small cap cancer companies. One of his big picks recently was Celator Pharmaceuticals (CPXX). He loaded up on millions of shares of this really small cap cancer company just 3 weeks before the company got bought out for over $3B. The share price rocketed from about $2 to $30.25 in less than a couple months.
Oncosec also recently completed a secondary offering and is well funded. They raised $20M in that offering, which is almost a fourth of the company’s value – just with cash in the bank!
That gives time for the trade to develop, and if great trial data hits, we could be in store for a large move. I think the risk to reward here is greatly in our favor.
5000$ = 6800 ONCS price 0.73
Tp ... from 2 - 15$